Skip to main content

Ask RayNew Trends Ads Appearances Podcasts API

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.

Eyewire News: The Podcast

Eyewire News: The Podcast

Viridian Executive Discusses FDA Approval of New TED Therapy

Jul 1, 2026 · 14 min · 7 segments

An executive from Viridian discusses the FDA approval of Lumvoa for thyroid eye disease (TED); a biosimilar referencing Lucentis is relaunched in the US; and Lumibird introduces a wireless integrated…

An executive from Viridian discusses the FDA approval of Lumvoa for thyroid eye disease (TED); a biosimilar referencing Lucentis is relaunched in the US; and Lumibird introduces a wireless integrated laser-indirect-ophthalmoscope. Learn more about your ad choices. Visit megaphone.fm/adchoices

An executive from Viridian discusses the FDA approval of Lumvoa for thyroid eye disease (TED); a biosimilar referencing Lucentis is relaunched in the US; and Lumibird introduces a wireless integrated…

Spotify Apple Podcasts YouTube Amazon Music Website

Speakers: Sean WuGuestKendall O'ConnorHostStephen Daly

Top entities: Graves' ophthalmopathy×17 Food and Drug Administration×15 United States×7 Ranibizumab×4 Lumibird SA×6

Show signals: SuitabilitySafeBiasNot politicalAudience≈9k followers

Post-Interview Lumvoa Recap10:53 – 11:09

Kendall O'ConnorHost

10:53

Lumvoa becomes the second FDA-approved pharmacologic treatment for TED.

Kendall O'ConnorHost

10:57

Horizon Therapeutics received FDA approval for Tepeza in 2020.

Kendall O'ConnorHost

11:01

In 2023, Amgen acquired Horizon for $27.8 billion, gaining rights to Tepeza.

Kendall O'ConnorHost

11:07

Viridian said it plans to launch Lumvoa immediately.

Graves' ophthalmopathyEntityDisorder
97%17 mentions
Food and Drug AdministrationGovernment OrganizationFederal agency
91%15 mentions
United StatesCountryCountry in North America
84%7 mentions
RanibizumabEntityDrug
78%4 mentions
Lumibird SACompanyCompany
72%6 mentions
Viridian TherapeuticsCompanyBiotech company
66%4 mentions
Insulin-like growth factor 1 receptorEntity
59%4 mentions
AmgenCompanyBiotech company
53%2 mentions
BiogenCompanyBiotechnology company
47%2 mentions
EuropeContinentContinent
41%2 mentions
MontrealCityCity in Québec, Canada
34%2 mentions
United KingdomCountryCountry in Europe
28%2 mentions
Horizon TherapeuticsCompanyBiotech company
22%1 mention
European CommissionGovernment OrganizationAdministrative body
16%1 mention
AfliberceptEntityMedication
9%1 mention
CanadaCountryCountry in North America
3%1 mention

PharmaceuticalsHealthcare
Treatment AccessibilityHealth > Patient Care
Patient CareHealth
FDA ProcessesHealthcare > Pharmaceuticals > Drug Approval
Drug ApprovalHealthcare > Pharmaceuticals
Pivotal StudiesHealthcare > Clinical Trials
Market AnalysisBusiness
Autoimmune DiseasesHealth > Medical Conditions
Medical ConditionsHealth
Clinical TrialsHealthcare
Pharmaceutical MarketBusiness > Market Analysis
Health
Business
Healthcare
Thyroid Eye DiseaseHealth > Medical Conditions > Autoimmune Diseases
Treatment OptionsHealth > Medical Conditions > Autoimmune Diseases > Thyroid Eye Disease
Market LaunchHealthcare > Pharmaceuticals > Drug Approval > FDA Processes
Market ShareBusiness > Market Analysis > Pharmaceutical Market
Competitive LandscapeBusiness > Market Analysis > Pharmaceutical Market > Market Share
Patient Support ProgramsHealth > Patient Care > Treatment Accessibility
Reimbursement StrategiesHealth > Patient Care > Treatment Accessibility > Patient Support Programs
Treatment EfficacyHealthcare > Clinical Trials > Pivotal Studies
Patient OutcomesHealthcare > Clinical Trials > Pivotal Studies > Treatment Efficacy

Post-Interview Lumvoa Recap10:53 – 11:09

Kendall O'ConnorHost

10:53

Lumvoa becomes the second FDA-approved pharmacologic treatment for TED.

Kendall O'ConnorHost

10:57

Horizon Therapeutics received FDA approval for Tepeza in 2020.

Kendall O'ConnorHost

11:01

In 2023, Amgen acquired Horizon for $27.8 billion, gaining rights to Tepeza.

Kendall O'ConnorHost

11:07

Viridian said it plans to launch Lumvoa immediately.

Sign up to see more

The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode

Create an account Already have an account? Log in

No account is needed to search Radar.